Department of Breast and Thyroid Surgery, Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, 321000, People's Republic of China.
Department of Cardiology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, 310014, People's Republic of China.
Cell Tissue Res. 2021 Apr;384(1):1-12. doi: 10.1007/s00441-020-03364-w. Epub 2021 Jan 12.
Mesenchymal stem cell (MSC)-based tissue regeneration therapy has been extensively investigated for cardiac regeneration over the past two decades. Numerous animal and clinical investigations demonstrated the efficacy of various types of MSCs towards myocardial protection and restoration against anthracycline-induced cardiotoxicity (AIC). It has been established that local or systemic administration of MSCs considerably improved the cardiac function, while ameliorating inflammatory responses and myocardial fibrosis. Several factors influence the outcomes of MSC treatment for AIC, including MSC types, dosages, and routes and duration of administration. In this review, we discuss the recent (from 2015 to 2020) experimental and clinical research on the preventive and regeneration efficacy of different types of MSCs (with or without supporting agents) against AIC, as well as the key factors responsible for MSC-mediated cardiac repair. In addition, challenges and future perspectives of MSC-based cardiac regeneration therapy are also outlined.
在过去的二十年中，基于间充质干细胞（MSC）的组织再生疗法已广泛用于心脏再生的研究。大量的动物和临床研究表明，各种类型的 MSC 对蒽环类药物诱导的心脏毒性（AIC）具有心肌保护和修复作用。已经证实，MSC 的局部或全身给药可显著改善心脏功能，同时改善炎症反应和心肌纤维化。有几个因素影响 MSC 治疗 AIC 的效果，包括 MSC 类型、剂量、给药途径和时间。在这篇综述中，我们讨论了最近（2015 年至 2020 年）关于不同类型的 MSC（有或没有支持剂）预防和再生 AIC 的实验和临床研究，以及负责 MSC 介导的心脏修复的关键因素。此外，还概述了基于 MSC 的心脏再生治疗的挑战和未来展望。
